Novel Treatments for TTR Amyloidosis | JACC Journal Club

In this JACC Journal Club session, we explore groundbreaking research on novel therapies for transthyretin (TTR) amyloidosis featuring Drs. Matthew Maurer and Michelle Kittleson. Learn how acoramidis and vutrisiran impact survival, how biomarkers like serum TTR/prealbumin guide therapy, and why early diagnosis is critical. This expert-led discussion offers clinical insights on managing ATTR-CM, optimizing treatment strategies, and improving patient access to care.

Episode metadata supplied by the publisher feed · Published Sep 16, 2025

Embed this episode

Attribution link and audio player

NOW PLAYING

Novel Treatments for TTR Amyloidosis | JACC Journal Club

0:00 58:09

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of JACC Journal Club?

This episode is 58 minutes long.

When was this JACC Journal Club episode published?

This episode was published on September 16, 2025.

Can I download this JACC Journal Club episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!